R
Ryan M. Young
Researcher at National Institutes of Health
Publications - 42
Citations - 9352
Ryan M. Young is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Diffuse large B-cell lymphoma & breakpoint cluster region. The author has an hindex of 22, co-authored 37 publications receiving 7542 citations. Previous affiliations of Ryan M. Young include Anschutz Medical Campus & Cornell University.
Papers
More filters
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Journal ArticleDOI
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo,Vu N. Ngo,Ryan M. Young,Roland Schmitz,Sameer Jhavar,Wenming Xiao,Kian-Huat Lim,Holger Kohlhammer,Weihong Xu,Yandan Yang,Hong Zhao,Arthur L. Shaffer,Paul B. Romesser,George E. Wright,John Powell,Andreas Rosenwald,Hans K. Müller-Hermelink,German Ott,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Denny D. Weisenburger,Wing C. Chan,Louis M. Staudt +31 more
TL;DR: The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported.
Journal ArticleDOI
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Roland Schmitz,George E. Wright,Da-Wei Huang,Calvin A. Johnson,James D. Phelan,James Q. Wang,Sandrine Roulland,Monica Kasbekar,Ryan M. Young,Arthur L. Shaffer,Daniel J. Hodson,Wenming Xiao,Xin Yu,Yandan Yang,Hong Zhao,Weihong Xu,Xuelu Liu,Bin Zhou,Wei Du,Wing C. Chan,Elaine S. Jaffe,Randy D. Gascoyne,Joseph M. Connors,Elias Campo,Armando López-Guillermo,Andreas Rosenwald,German Ott,Jan Delabie,Lisa M. Rimsza,Kevin Tay Kuang Wei,Andrew D. Zelenetz,Andrew D. Zelenetz,John P. Leonard,John P. Leonard,Nancy L. Bartlett,Nancy L. Bartlett,Bao Tran,Jyoti Shetty,Yongmei Zhao,Dan R. Soppet,Stefania Pittaluga,Wyndham H. Wilson,Louis M. Staudt +42 more
TL;DR: Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on “chronic active” B‐cell receptor signaling that is amenable to therapeutic inhibition, and an algorithm was developed and implemented to discover genetic subtypes based on the co‐occurrence of genetic alterations.
Journal ArticleDOI
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson,Ryan M. Young,Roland Schmitz,Yandan Yang,Stefania Pittaluga,George E. Wright,Chih Jian Lih,P. Mickey Williams,Arthur L. Shaffer,John F. Gerecitano,John F. Gerecitano,Sven de Vos,Andre Goy,Vaishalee P. Kenkre,Paul M. Barr,Kristie A. Blum,Andrei R. Shustov,Ranjana H. Advani,Nathan Fowler,Julie M. Vose,Rebecca Elstrom,Thomas M. Habermann,Jacqueline C. Barrientos,Jesse McGreivy,Maria Fardis,Betty Y. Chang,Fong Clow,Brian Munneke,Davina Moussa,Darrin M. Beaupre,Louis M. Staudt +30 more
TL;DR: The selective development of ibrutinib for the treatment of ABC DLBCL is supported, with the highest number of responses occurred in ABC tumors that lacked BCR mutations, suggesting that oncogenic BCR signaling in ABC does not require B CR mutations and might be initiated by non-genetic mechanisms.
Journal ArticleDOI
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz,Ryan M. Young,Michele Ceribelli,Sameer Jhavar,Wenming Xiao,Meili Zhang,George E. Wright,Arthur L. Shaffer,Daniel J. Hodson,Eric Buras,Xuelu Liu,John Powell,Yandan Yang,Weihong Xu,Hong Zhao,Holger Kohlhammer,Andreas Rosenwald,Philip M. Kluin,Hans Konrad Müller-Hermelink,German Ott,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Martin D. Ogwang,Steven J. Reynolds,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Stefania Pittaluga,Wyndham H. Wilson,Thomas A. Waldmann,Martin Rowe,Sam M. Mbulaiteye,Alan B. Rickinson,Louis M. Staudt +41 more
TL;DR: High-throughput RNA sequencing and RNA interference screening is used to discover essential regulatory pathways in Burkitt's lymphoma that cooperate with MYC, the defining oncogene of this cancer.